Weizmann Institute Using GSI Technology’s Gemini-I® APU to Accelerate Search for Coronavirus Treatments

Rhea-AI Summary

GSI Technology, Inc. (Nasdaq: GSIT) has published a white paper detailing its collaboration with the Weizmann Institute to aid in COVID-19 treatment research. Utilizing GSI's Gemini APU, the Weizmann scientists can execute rapid similarity structure searches on a database of 40 million compounds to identify potential antiviral treatments. The Gemini APU significantly reduces response times from minutes to seconds compared to traditional CPUs. This partnership aims to discover active compounds that may be beneficial in treating COVID-19, particularly similar to the antiviral, Remdesivir.

Positive

• Collaboration with Weizmann Institute enhances research capabilities for COVID-19 treatments.
• Gemini APU accelerates drug discovery by executing rapid data processing.
• Ability to perform searches on a 40 million compound database increases chances of finding effective treatments.

Negative

• None.

SUNNYVALE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- GSI Technology, Inc. (Nasdaq: GSIT), a leading provider of high-performance memory solutions for the networking, telecommunications and military markets, and developer of the Gemini^® Associative Processing Unit (APU), published a white paper on GSI Technology’s role in helping researchers at the Weizmann Institute in the search for COVID-19 treatments.

The white paper discusses how the Weizmann Institute is using the Gemini APU, GSI's patented in-memory processing technology, to search for active chemical structures, including compounds that can target the coronavirus. This new breed of processor performs massive parallel data processing, compute, and search directly in the memory array.

Lee-Lean Shu, Chairman and Chief Executive Officer of GSI Technology, commented, "We are excited to be working with the Weizmann Institute to accelerate the discovery of active compounds that may prove useful in COVID-19 treatments. The Gemini-I APU is being used by researchers to identify compounds structurally similar to Remdesivir, an antiviral drug recently shown to be effective in treating severe COVID-19 patients. Compared to a CPU, our processor speeds up discovery by performing multiple versus solitary searches and reducing response times from many minutes to seconds."

Researchers at the Weizmann Institute of Science, in Rehovot, Israel, and The Nancy & Stephen Grand Israel National Center for Personalized Medicine (G-INCPM), which is based at and managed by the Weizmann Institute, have installed a board with the GEMINI-I APU. G-INCPM's multidisciplinary teams of scientists and clinicians, working in collaboration with biomedical and pharmaceutical companies, conduct research involving genomics, protein profiling, bioinformatics, and drug discovery, translating those insights to the clinic for the benefit of human health.

A central premise of medicinal chemistry is that structurally similar molecules exhibit similar biological activities. The coronavirus (SARS-CoV-2) is related to SARS-Cov, responsible for the SARS outbreak of the early 2000s. Remdesivir is an antiviral drug that has been shown in laboratory tests to be effective against SARS-Cov. Weizmann researchers, working with the Gemini APU and using Remdesivir as their query molecule, can perform very rapid similarity structure searches on an in-house database of 40 million compounds in their search for compounds to develop new treatments for COVID-19 patients.

Please use this link to view the Company’s publication “Introducing a “Cheminformatics Similarity Structure Search Solution” https://www.gsitechnology.com/Introducing-a-Cheminformatics-Similarity-Structure-Search-Solution.

ABOUT GSI TECHNOLOGY

Founded in 1995, GSI Technology, Inc. is a leading provider of semiconductor memory solutions. GSI’s resources are currently focused on bringing new products to market that leverage existing core strengths, including radiation-hardened memory products for extreme environments, and Gemini, the APU designed to deliver performance advantages for diverse artificial intelligence applications. GSI Technology is headquartered in Sunnyvale, California and has sales offices in the Americas, Europe, and Asia.  For more information, please visit www.gsitechnology.com.

Contacts:
Investor Relations:
Hayden IR
Kim Rogers
385-831-7337

Company:
GSI Technology, Inc.
Douglas M. Schirle
Chief Financial Officer
408-331-9802

FAQ

What is the role of GSI Technology in COVID-19 research?

GSI Technology collaborates with the Weizmann Institute using their Gemini APU to aid in the search for COVID-19 treatments.

How does the Gemini APU benefit COVID-19 treatment research?

The Gemini APU enables rapid similarity structure searches, reducing response times from minutes to seconds, enhancing research efficiency.

What compounds are being targeted in the search for COVID-19 treatments?

Researchers are focusing on compounds structurally similar to Remdesivir, an antiviral drug effective against severe COVID-19 cases.

What is the significance of the white paper released by GSI Technology?

The white paper outlines GSI's partnership with the Weizmann Institute and details how their technology is being utilized in COVID-19 research.

How many compounds can the Gemini APU analyze?

The Gemini APU can perform similarity structure searches on a database containing 40 million compounds.